Acquisitions in Groningen, Netherlands

Showing 3 transactions.

  • Summa Equity Acquires Majority Stake in Bollegraaf Group
    September 17, 2024
    Buyer
    Summa Equity
    Target
    Bollegraaf Group
    Seller
    Capital A Investment Partners
    Industry
    Manufacturing
    Location
    Groningen, Netherlands
    Type
    Buyout

    Stockholm-based impact investor Summa Equity has acquired a majority stake in Netherlands-headquartered Bollegraaf Group, a global provider of turnkey recycling and waste‑sorting solutions. Summa is investing from its EUR 2.3 billion Fund III to accelerate Bollegraaf’s growth, expand innovation in mechanical recycling technologies and drive the transition to a circular economy; the seller is Capital A Investment Partners and the deal is expected to close following regulatory approvals in October 2024.

  • IK Partners Invests in Defibrion B.V.
    July 23, 2024
    Buyer
    IK Partners
    Target
    Defibrion B.V.
    Seller
    Holland Capital, Joshua Valkenier, Management team
    Industry
    Medical Devices
    Location
    Groningen, Netherlands
    Type
    Growth capital

    IK Partners’ Small Cap III fund has signed an agreement to invest in Defibrion B.V., a Groningen-based distributor of automated external defibrillators (AEDs) and related emergency-response equipment. IK is acquiring its stake from existing shareholders including Holland Capital, while co-founder and CEO Joshua Valkenier and the management team will reinvest; the capital will be used to scale the platform, expand direct end-customer channels and pursue buy-and-build consolidation opportunities.

  • Keensight Capital Acquires Majority Stake in Symeres from Gilde Healthcare
    May 25, 2021
    Buyer
    Keensight Capital, Symeres management
    Target
    Symeres
    Seller
    Gilde Healthcare
    Location
    Groningen, Netherlands
    Type
    Buyout

    Keensight Capital will acquire a majority stake in Symeres, a leading European small-molecule CRO and CDMO, from Gilde Healthcare with management co-investing. The investment will fund organic growth and further M&A to expand Symeres' drug discovery, development and manufacturing capabilities across Europe and globally.